SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as its Q4 earnings beat was met with a cautious Q1 outlook and projections for increased content spending, creating a split in community sentiment. While many see the current dip as a significant buying opportunity, citing strong fundamentals and the potential content benefits from the pending Warner Bros. acquisition, others remain concerned about the associated debt, a pause in buybacks, and signs of maturing growth.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas ($BOIL) is surging dramatically due to extreme cold weather forecasts and polar vortex threats across the US, signaling expectations of substantial natural gas demand and potential production impacts. The community is abuzz with discussions of massive gains and short squeezes, grappling with the asset's inherent volatility as many celebrate long positions while others caution about a potential reversal. This intense debate reflects the highly weather-sensitive nature of natural gas and its leveraged ETFs.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending as investors flock to gold amidst escalating geopolitical tensions, driven by recent tariff threats against European nations linked to discussions around Greenland. This has ignited fears of a global trade conflict and broader market instability, leading the community to embrace gold as a crucial safe-haven and non-political reserve asset.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is experiencing significant volatility, declining sharply as natural gas prices surge amidst forecasts for an intense cold snap and potential polar vortex activity, which is driving up heating demand. This dramatic movement has fueled extensive community debate, with many viewing KOLD's steep drop as a potential "buy the dip" opportunity while others caution about the inherent risks and rapid reversals characteristic of leveraged natural gas products.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending with significant community enthusiasm surrounding its strategic pivot towards AI cloud infrastructure, underscored by its substantial Microsoft deal and whispers of further partnerships with major AI sector players. Its strong performance, often decoupling from Bitcoin trends, is attributed to its valuable power assets and data center capacity, a critical advantage in the booming AI compute market. Positive analyst upgrades and favorable trade developments, like the U.S.-Taiwan deal impacting AI chip tariffs, are further fueling bullish sentiment.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano (ADA) is drawing significant attention, with proponents highlighting a recent governance milestone and ongoing developments like Google Cloud's staking pool and potential CME futures as catalysts for an upward trajectory. Conversely, a vocal segment of the community expresses deep skepticism, labeling ADA a "scam coin" and debating if current price movements signal a "third wave rally" or further declines amidst broader altcoin market volatility.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is a key focus of market discussion amidst heightened volatility, primarily driven by concerns around geopolitical rhetoric on tariffs and the proposed acquisition of Greenland. While some traders express frustration over perceived market manipulation and "liquidity injections," others anticipate a rapid recovery, positioning for a potential bounce in tech leadership.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing significant conversation following upbeat financial updates, including reiterated revenue targets and a stronger cash outlook, alongside global regulatory filings for its flu vaccine and ongoing pipeline progress in oncology. The community is actively discussing potential short squeezes due to high short interest and the long-term value of its diversified mRNA platform, though some skepticism from past vaccine controversies remains. This resurgence aligns with a broader momentum shift observed within the biotech sector.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending following robust Phase 1 clinical trial results for its eczema treatment, soquelitinib, which demonstrated significant efficacy and a favorable safety profile. This promising data initially drove a notable surge, but the company's subsequent announcement of a proposed public offering has ignited community debate over potential share dilution and its implications for future trials.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending amidst a sharply divided community, driven by the impending TikTok U.S. operations deal, expected to finalize around January 22nd, which bulls anticipate will fuel a significant rebound. However, this optimism is significantly challenged by a recent bondholder lawsuit alleging undisclosed debt for its ambitious AI infrastructure buildout. Bears are amplifying concerns over the company's escalating debt and potential financial risks, creating a volatile debate between long-term growth prospects in AI and immediate solvency fears.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 7.4% - What's Next?

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 7.4% - Here's What Happened...

Iovance Biotherapeutics (NASDAQ:IOVA) Trading Down 7.1% - Here's What Happened

Iovance Biotherapeutics (NASDAQ:IOVA) Trading Down 7.1% - Should You Sell...

Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 8.7% - Still a Buy?

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 8.7% - Here's Why...

Iovance Biotherapeutics, Inc. $IOVA Position Increased by Squarepoint Ops LLC

Squarepoint Ops LLC grew its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 115.2% in the 2nd quarter, according to the company in its most recent Form 13F filing...

Mirador Capital Partners LP Makes New Investment in Iovance Biotherapeutics, Inc. $IOVA

Mirador Capital Partners LP purchased a new stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) in the 3rd quarter, according to its most recent 13F filing with the...

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 6.7% - Should You Buy?

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 6.7% - What's Next...

Voss Capital LP Acquires New Shares in Iovance Biotherapeutics, Inc. $IOVA

Voss Capital LP acquired a new position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities...

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 7.9% - What's Next?

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 7.9% - Here's Why...

Kennondale Capital Management LLC Invests $384,000 in Iovance Biotherapeutics, Inc. $IOVA

Kennondale Capital Management LLC purchased a new stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) during the 2nd quarter, according to its most recent filing with the...

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 7.8% - Here's Why

Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 7.8% - Here's Why...

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.17	--	--	N/A
Q3 '25	-$0.26	-$0.25	2.98%	BEAT
Q2 '25	-$0.28	-$0.33	-16.70%	MISSED
Q1 '25	-$0.24	-$0.36	-48.93%	MISSED
Q4 '24	-$0.27	-$0.26	2.88%	BEAT

IOVA
Iovance Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest IOVA News

IOVAIovance Biotherapeutics Inc